Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000436581

Medchemexpress LLC 9-ING-41 (Elraglusib) | 1034895-42-5 | 99.1% | 404.35 | 1 ML
SDP

Catalog No. 5000436581
Encompass_Preferred

9-ING-41 (Elraglusib) is a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor. With an IC50 of 0.71 μM, it leads to cell cycle arrest, autophagy, and apoptosis in cancer cells. This compound exhibits significant anticancer activity and has the potential to enhance the antitumor effects of various chemotherapeutic agents.

  • Maleimide-based ATP-competitive and selective GSK-3β inhibitor
  • Induces cell cycle arrest
  • Promotes autophagy
  • Induces apoptosis in cancer cells
  • Exhibits anticancer activity
  • Enhances antitumor effects of chemotherapeutic agents

Catalog No. 50-004-36581 Supplier Medchemexpress LLC Supplier No. HY11391410MM/1ML
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

9-ING-41 (Elraglusib) is a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor. With an IC50 of 0.71 μM, it leads to cell cycle arrest, autophagy, and apoptosis in cancer cells. This compound exhibits significant anticancer activity and has the potential to enhance the antitumor effects of various chemotherapeutic agents.

  • Maleimide-based ATP-competitive and selective GSK-3β inhibitor
  • Induces cell cycle arrest
  • Promotes autophagy
  • Induces apoptosis in cancer cells
  • Exhibits anticancer activity
  • Enhances antitumor effects of chemotherapeutic agents

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.